Executive Summary
Hospital TAVR volume — not county income, insurance mix, or racial composition — drove 30-day stroke and mortality across 85 California centers in a CMS-database analysis published in the Journal of the American College of Surgeons, reinforcing that where a patient gets a TAVR matters more than the ZIP code they live in. A companion systematic review of TMVR vs TEER for mitral regurgitation found TMVR delivered more complete MR resolution but at higher 30-day mortality and more myocardial infarction, malposition, and valve migration, and an early Evoque TTVR series in carcinoid heart disease pushed transcatheter tricuspid replacement into a population explicitly excluded from TRISCEND II. The day tightens the case for volume-based TAVR referral and complicates the case for TMVR as a routine TEER alternative.
- Each log-unit increase in TAVR volume was associated with lower 30-day stroke (β=-0.541, p=0.001) and mortality (β=-0.334, p=0.046) across 336 hospital-year observations (JACS).
- Seven carcinoid heart disease patients underwent Evoque TTVR with procedural success and TR reduced to mild or less, but two developed intraoperative carcinoid crisis and one required salvage SAPIEN S3 valve-in-Evoque deployment (CCI).
- Systematic review found TMVR achieved deeper MR reduction and greater LV reverse remodeling than TEER but carried significantly higher 30-day mortality with exclusive rates of MI, prosthesis malposition, and valve migration (Cardiovascular Therapeutics).
- First-in-human Venus P-Valve implanted inside a degenerated Myval balloon-expandable pulmonary valve in a repaired tetralogy patient extends valve-in-valve options in the pulmonary position (JACC Case Reports).
- Y-incision aortic root enlargement in 11 CT-analyzed patients increased annular area from 3.9 to 4.6 cm² without breaching valve-to-coronary or valve-to-aorta risk thresholds, preserving future TAV-in-SAV options (Gen Thorac Cardiovasc Surg).
What to watch: TCT 2026 next month will bring updated EARLY TAVR subgroup data and further follow-up on transcatheter tricuspid replacement platforms competing with Evoque.
Aortic Valve (TAVR/TAVI)
Volume, not ZIP code, is the reproducible driver of TAVR quality. The California CMS analysis of 85 hospitals over 2022–2023 found that each log-unit rise in institutional TAVR volume tracked with lower risk-adjusted 30-day stroke (β=-0.541, p=0.001) and mortality (β=-0.334, p=0.046), while county-level income, insurance coverage, and racial composition failed to hold significance after adjustment (JACS). The stroke signal survived sensitivity analysis using observed-to-expected ratios; mortality did not. The accompanying editorial from Narahari, Phillips, and Kron reinforces the volume-outcomes argument that has anchored SAVR referral patterns for decades and now applies squarely to TAVR. This is an ecological study — it cannot exclude patient-level disparities and cannot identify which care-delivery features at high-volume centers actually protect against stroke. It does undercut the argument that community-level access alone explains outcome gaps.
Neither ACC/AHA 2020 nor ESC 2025 sets a minimum institutional TAVR volume threshold, though both endorse Heart Team-based delivery. As ESC 2025 lowers the TAVI-preferred age threshold to 70, the volume-outcome relationship becomes more consequential: more patients funneled to more centers means the distribution of volume matters. A separate case report described combined TAVR + endovascular aortic repair for aortitis following prior valve-sparing root and frozen elephant trunk, illustrating how transcatheter salvage is now expected after complex open reconstructions.
Mitral Valve (MitraClip, PASCAL, TMVR)
TMVR buys deeper MR reduction and pays for it in 30-day mortality. A systematic review comparing transcatheter mitral valve replacement to TEER across observational studies and case series found TMVR delivered more frequent MR ≤1+ outcomes, complete MR resolution, near-laminar flow, and greater LVEDVI/LVESVI improvement (Cardiovascular Therapeutics). The trade-off: significantly higher 30-day mortality, more acute kidney injury, bleeding, stroke, and access-site events, plus TMVR-exclusive myocardial infarction, prosthesis malposition, and valve migration. Pooled 1-year mortality did not differ significantly. The review is non-randomized, dominated by heterogeneous single-arm data, and heavily confounded by selection — TMVR patients tend to be anatomically unsuited for TEER.
ESC 2025 rates TEER for ventricular secondary MR as Class I, LOE A on the strength of COAPT and RESHAPE-HF2; ACC/AHA 2020 sits at Class IIa. Surgical mitral repair remains preferred for degenerative MR with durable anatomy under both guidelines. TMVR carries no dedicated Class recommendation in either document — it remains an investigational or compassionate-use alternative for patients unsuitable for surgery or TEER. A separate Structural Heart editorial on persistent tricuspid regurgitation after mitral TEER reinforces that closing the mitral leak often unmasks, not resolves, right-sided disease — anticipate TR early and reassess.
Tricuspid Valve (TriClip, TTVR)
Evoque TTVR is being tested in populations TRISCEND II excluded, with predictable friction. Seven carcinoid heart disease patients across two tertiary centers underwent Evoque transcatheter tricuspid valve replacement; all achieved procedural success with TR reduced to mild or less and NYHA improvement at median 9-month follow-up, and four showed RV basal diameter reduction (CCI). Two developed intraoperative carcinoid crisis; one required in-Evoque SAPIEN S3 salvage deployment. Non-randomized, N=7, two centers — hypothesis-generating at best. It addresses a genuine gap: surgical TR replacement in carcinoid heart disease carries high operative mortality, and TRISCEND II excluded these patients entirely.
ESC 2025 rates transcatheter tricuspid treatment Class IIa, LOE A for high-risk symptomatic severe TR without severe RV dysfunction or pre-capillary pulmonary hypertension. ACC/AHA 2020 does not address transcatheter TR therapy — trials had not read out. Carcinoid TR sits outside the ESC's endorsed population and outside every RCT to date. The crisis risk observed here (2/7) means operators need endocrinology and anesthesia teams primed for octreotide rescue. Extending TTVR indications faster than trial evidence is exactly the pattern the field has been warned about.
Surgical vs. Transcatheter Comparisons
Y-incision aortic root enlargement preserves future TAV-in-SAV options. Post-op CT in 11 patients with small aortic annuli demonstrated annular area rising from 3.9 to 4.6 cm² (p=0.014) with sinus of Valsalva and sinotubular junction enlargement, unchanged LVOT area, and mean valve-to-coronary distances of 7.9 mm (LCA) and 6.4 mm (RCA) — none breached the ≤4 mm high-risk threshold for future valve-in-valve planning (Gen Thorac Cardiovasc Surg). Thirty-day mortality was zero. Small series, single-center, no long-term follow-up — but the imaging-driven argument is that a well-planned SAVR plus root enlargement gives a small-annulus patient a larger prosthesis today and TAV-in-SAV feasibility tomorrow. This is the lifetime-management logic ESC 2025 explicitly foregrounds. For a 60-year-old with a 19 mm annulus, the surgical-first sequence remains defensible on both prosthesis-patient mismatch grounds and future reintervention grounds.
Device & Technology
First-in-human Venus P-Valve implantation inside a dysfunctional Myval balloon-expandable pulmonary valve (JACC Case Reports) extends valve-in-valve into cross-platform territory — a self-expanding platform deployed within a balloon-expandable scaffold in a 26-year-old with repaired tetralogy of Fallot. Successful, single case, and the take-home is narrow: with adequate landing-zone length and scaffold preparation, prior balloon-expandable pulmonary valves can accept self-expanding valve-in-valve rescue. A separate EHJ-Cardiovascular Imaging piece on intravascular ultrasound during TAVR flags growing interest in IVUS-guided periprocedural anatomy assessment, though clinical impact remains unproven.
Industry & Market
Firstpost's World Heart Day coverage delivers the predictable consumer-facing narrative that TAVR and MitraClip have "revolutionized" valve care — a framing that omits durability uncertainty beyond 10 years and the guideline disagreement on TAVR age thresholds (ACC/AHA ≥65 shared-decision, ESC ≥70 preferred). The device story remains more complicated than the press-release version.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $87.05, +0.88% on the day; 6-month +9.50%
- Market cap $50.2B; trailing P/E 51.8, forward 25.8; beta 0.85; 52-week $72.30–$96.29
- Analyst target $100.96 (range $84–$110, 26 analysts); consensus Buy
- Next earnings 2026-10-29 (EPS est $0.74, Rev est $1.68B)
Edwards continues to trade on TAVR volume growth and its transcatheter tricuspid franchise (EVOQUE). The JACS volume-outcomes signal reinforces the moat around established high-volume TAVR programs where SAPIEN dominates.
Medtronic (MDT)
- Close: $88.33, -0.35% on the day; 6-month +4.80%
- Market cap $113.0B; trailing P/E 21.8, forward 13.8; beta 0.57; 52-week $73.31–$106.33
- Analyst target $104.83 (range $85–$121, 24 analysts); consensus Buy
- Next earnings 2026-11-17 (EPS est $1.33, Rev est $9.48B)
Evolut's low-risk long-term durability narrative remains the swing factor. ESC 2025 lowers the TAVI-preferred threshold to age 70, positioning Medtronic's supra-annular platform directly in the 70–80 cohort now steered toward transcatheter.
Abbott (ABT)
- Close: $101.19, -0.10% on the day; 6-month +0.66%
- Market cap $175.1B; trailing P/E 32.8, forward 16.7; beta 0.59; 52-week $81.97–$135.45
- Analyst target $120.26 (range $103–$135, 25 analysts); consensus Buy
- Next earnings 2026-10-14 (EPS est $1.42, Rev est $12.99B)
The MitraClip franchise faces a real tension: the TMVR-vs-TEER systematic review confirms TEER's safety edge, which supports MitraClip volumes, but Abbott is simultaneously advancing Tendyne and Navitor in TMVR — where the 30-day mortality gap the review flagged remains the clinical hurdle.
Boston Scientific (BSX)
- Close: $43.83, -0.19% on the day; 6-month -30.34%
- Market cap $63.5B; trailing P/E 17.8, forward 12.8; beta 0.57; 52-week $42.20–$105.65
- Analyst target $61.00 (range $44–$94, 29 analysts); consensus Buy
- Next earnings 2026-10-28 (EPS est $0.77, Rev est $5.15B)
The 30% six-month drawdown reflects structural repricing following the ACURATE neo2 discontinuation and continued questions about the WATCHMAN and EP franchises. Analyst targets remain well above spot, but the delta between $44 (low) and $94 (high) reflects deep disagreement about the growth trajectory.
Anteris Technologies (AVR.AX)
- Last close $10.69 (Sep 25); market cap ~$1.0B; forward P/E -4.97 (pre-revenue)
- 52-week range $5.20–$15.47
- Single analyst target $13.00; no consensus recommendation
DurAVR remains a pre-commercial story tied to pivotal trial progression. The stock has given back roughly a third of its July highs.
Market outlook: The structural heart sector's dispersion (EW +9.5%, BSX -30.3% over six months) reflects idiosyncratic pipeline news rather than sector-wide fatigue. ESC 2025 pushes TAVI earlier and expands transcatheter tricuspid indications; the volume-outcomes evidence published today argues for continued consolidation of procedures at experienced centers — favorable for incumbents (EW, MDT) that already dominate high-volume programs and less favorable for challengers dependent on breadth of adoption.
What's Next
The next inflection points are TCT 2026 with expected updates on EARLY TAVR asymptomatic subgroups, further TRISCEND II follow-up beyond one year, and any signal on whether TMVR platforms can close the 30-day mortality gap against TEER. Until then, the practical takeaway from today's evidence: refer TAVR to high-volume centers, favor TEER over TMVR for MR unless anatomy forces the issue, and treat carcinoid TTVR as experimental salvage — not a new standard.
— E. Nolan Beckett, MD